VE point estimates against H3N2-related illness varied by age group; statistically significant protection was found against H3N2-related illness among children aged 6 months through 8 years (VE = 53%; CI = 16%–74%) and adults aged 50–64 years (VE = 50%; CI = 23%–67%), whereas protection in other age groups did not reach statistical significance.
← all excerpts
Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017.
1
—
—